Skip to main content
    E

    Evolus Inc (EOLS)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $7.35
    -0.17 (-2.26%)

    Market Cap: $485.47M

    Last updated: Oct 30, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    51%(18/35)
    Avg Surprise
    -12.37%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.07
    Range$-0.08 - $-0.06
    4 analysts
    EPS RevisionsNo revisions (7d)
    2
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.07+3.6%
    60d ago$-0.06-12.5%
    30d ago$-0.06-12.5%
    7d ago$-0.06-12.5%
    Current$-0.07
    Revenue Consensus
    $78M
    Range$77M - $78M
    6 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.18
    Range$0.13 - $0.20
    4 analysts
    Revenue Consensus
    $103M
    Range$102M - $105M
    6 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.18---
    Sep 26EST
    		-$-0.07---
    Jun 26
    Reported Aug 5
    		$-0.09$-0.09+0.00%Beat+65.4%
    Mar 26
    Reported May 4
    		$-0.05N/A+58.33%Beat+70.6%
    Dec 25
    Reported Mar 3
    		$0.01N/A-64.61%Miss-5.0%
    Sep 25
    Reported Nov 5
    		$-0.20$-0.26+23.08%Beat-11.1%
    Jun 25
    Reported Aug 5
    		$-0.26$-0.09-188.89%Miss-333.3%
    Mar 25
    Reported May 7
    		$-0.17$-0.14-21.43%Miss-54.5%
    Dec 24
    Reported Mar 4
    		$0.01$0.02-37.67%Miss+111.6%
    Sep 24
    Reported Nov 6
    		$-0.18$-0.11-63.64%Miss+0.0%
    Jun 24
    Reported Jul 31
    		$-0.06$-0.06+0.00%Beat+72.7%
    Mar 24
    Reported May 7
    		$-0.11$-0.08-37.50%Miss+35.3%
    Dec 23
    Reported Mar 7
    		$-0.12$-0.07-71.43%Miss+14.3%
    Sep 23
    Reported Nov 7
    		$-0.18$-0.18+0.00%Beat+37.9%
    Jun 23
    Reported Aug 2
    		$-0.22$-0.20-10.00%Miss+26.7%
    Mar 23
    Reported May 9
    		$-0.17$-0.16-6.25%Miss+29.2%
    Dec 22
    Reported Mar 8
    		$-0.14$-0.15+6.67%Beat+41.7%
    Sep 22
    Reported Nov 8
    		$-0.29$-0.29+0.00%Beat-3.6%
    Jun 22
    Reported Aug 2
    		$-0.30$-0.24-25.00%Miss-57.9%
    Mar 22
    Reported May 10
    		$-0.24$-0.33+27.27%Beat-20.0%
    Dec 21
    Reported Mar 3
    		$-0.24$-0.21-14.29%Miss+45.5%
    Sep 21
    Reported Nov 2
    		$-0.28$-0.27-3.70%Miss+15.2%
    Jun 21
    Reported Aug 4
    		$-0.19$-0.25+24.00%Beat+55.8%
    Mar 21
    Reported May 12
    		$-0.20N/A+53.49%Beat+73.3%
    Dec 20
    Reported Mar 24
    		$-0.44$-0.22-100.00%Miss+13.7%
    Sep 20
    Reported Oct 29
    		$-0.33$-0.37+10.81%Beat+65.6%
    Jun 20
    Reported Aug 10
    		$-0.43$-0.69+37.68%Beat+67.4%
    Mar 20
    Reported May 11
    		$-0.75$-0.62-20.97%Miss+8.5%
    Dec 19
    Reported Feb 25
    		$-0.51$-0.68+25.00%Beat-10.9%
    Sep 19
    Reported Nov 4
    		$-0.96$-1.14+15.79%Beat-152.6%
    Jun 19
    Reported Aug 12
    		$-1.32$-0.84-57.14%Miss-277.1%
    Mar 19
    Reported Apr 30
    		$-0.82$-0.62-32.26%Miss-173.3%
    Dec 18
    Reported Mar 18
    		$-0.46$-0.55+16.36%Beat-64.3%
    Sep 18
    Reported Nov 5
    		$-0.38$-0.42+9.52%Beat-46.2%
    Jun 18
    Reported Aug 2
    		$-0.35$-0.32-9.38%Miss-29.6%
    Mar 18
    Reported May 10
    		$-0.30$-0.36+16.67%Beat-76.5%
    Dec 17
    Reported Feb 9
    		$-0.28$-0.30+6.67%Beat-
    Sep 17
    Reported Nov 29
    		$-0.26$0.00N/AMiss-
    Jun 17
    Reported Aug 28
    		$-0.27$0.00N/AMiss-
    Mar 17
    Reported Jun 29
    		$-0.17$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-22.49EV/EBITDAN/A
    Price/FCF-22.13xFCF Yield-4.52%
    Profitability
    Profit Margin-10.80%Operating Margin-5.17%
    ROE-18730.00%ROIC-14.93%
    Financial Health
    Debt/Equity-5.07xInterest Coverage-1.16x
    Current Ratio1.70xQuick Ratio1.28x
    Trading Statistics
    Beta1.34Avg Volume784.53K
    52-Week High$9.3152-Week Low$3.86

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$7.36
    SMA 20$7.44
    SMA 50$7.98
    SMA 200$6.26
    EMA 10$7.40
    EMA 20$7.48
    EMA 50$7.59
    EMA 200$7.05

    MACD

    Line: -0.12Signal: -0.15Hist: 0.03

    ADX

    ADX: 16.8+DI: 23.2-DI: 22.4

    Aroon & PSAR

    Aroon Up12.0
    Aroon Down84.0
    PSAR$6.95

    Bollinger Bands

    Upper Band$7.88
    Lower Band$7.00
    %B Position1182%(Upper)
    Band Width0.39

    RSI (14-Day)

    Neutral
    46.1

    Momentum Oscillators

    Stoch %K64.7
    Stoch %D61.0
    Williams %R-51.6
    ROC (10d)3.5%
    Momentum0.25
    CCI (20d)-21.6
    MFI (14d)51.6

    Volatility Measures

    ATR (14d)$0.36(4.9%)
    StdDev (20d)0.22
    Hist Vol52.8%(High)

    Volume Flow

    VWAP$7.38
    OBV-21.6M
    AD Line-19.9M
    CMF (20d)0.126

    Volume Metrics

    Avg Vol (20d)713.3K
    Vol Ratio1.1x
    VWMA (20d)$7.46

    Pivot Points

    R3$8.22
    R2$8.03
    R1$7.77
    Pivot Point$7.58
    S1$7.32
    S2$7.13
    S3$6.87

    Advanced Oscillators

    TSI-9.35
    Ultimate Osc49.6
    KST-80.95

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$84.08M$73.14M$90.30M$68.97M$69.39M$68.52M$78.95M$61.09M$66.91M$59.33M$61.00M$50.02M
    Cost of Revenue$26.90M$24.24M$31.01M$23.13M$24.07M$21.87M$26.31M$18.99M$19.84M$18.83M$22.23M$15.43M
    Gross Profit$57.18M$48.90M$59.29M$45.84M$45.32M$46.66M$52.63M$42.10M$47.07M$40.50M$38.77M$34.59M
    Operating Expenses$61.72M$55.74M$55.07M$57.34M$55.53M$61.83M$54.95M$57.57M$54.77M$49.42M$47.41M$48.03M
    R&D$1.89M$2.24M$3.48M$2.05M$1.84M$2.21M$2.43M$2.31M$2.35M$2.08M$6.81M$1.59M
    SG&A$57.05M$51.98M$54.66M$52.82M$56.67M$56.64M$50.24M$52.51M$50.15M$45.12M$43.06M$43.33M
    Operating Income$-4,543,000$-6,848,000$4.22M$-11,500,000$-10,210,000$-15,172,000$-2,314,000$-15,473,000$-7,702,000$-8,922,000$-8,635,000$-13,440,000
    Interest Income$296,000$285,000$263,000$479,000$479,000$710,000$789,000$928,000$1.03M$517,000$291,000$306,000
    Interest Expense$4.17M$3.98M$3.98M$4.09M$7.21M$4.42M$4.57M$4.76M$4.70M$4.70M$4.08M$3.79M
    Income Before Tax$-8,206,000$-10,418,000$515,000$-15,570,000$-17,089,000$-18,820,000$-6,351,000$-19,036,000$-11,307,000$-13,062,000$-11,725,000$-16,899,000
    Income Tax Expense$-154,000$256,000$385,000$167,000$53,000$72,000$440,000$134,000$43,000$47,000$106,000$24,000
    Net Income$-8,052,000$-10,674,000$130,000$-15,737,000$-17,142,000$-18,892,000$-6,791,000$-19,170,000$-11,350,000$-13,109,000$-11,831,000$-16,923,000
    EBITDA$-1,236,000$-3,678,000$7.16M$-9,338,000$-8,005,000$-12,988,000$-657,000$-13,639,000$-5,778,000$-7,043,000$-6,151,000$-11,676,000
    EBIT$-4,330,000$-6,728,000$4.23M$-11,955,000$-10,361,000$-15,115,000$-2,567,000$-15,200,000$-7,640,000$-8,877,000$-7,941,000$-13,419,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about EOLS

    News

    Evolus to Participate in Upcoming November 2026 Investor Conferences in New York and London

    Evolus, Inc. announced its management team will participate in two investor conferences in November 2026. The Stifel Healthcare Conference in New York City on November 11 will include a fireside chat and investor...

    BioSpace•10/29/26•Somewhat-Bullish

    Evolus to Participate in Upcoming Investor Conferences in New York and London

    Evolus, Inc. announced that its management team will participate in two upcoming investor conferences: the Stifel Healthcare Conference in New York City on November 11, 2026...

    FinancialContent•10/28/26•Somewhat-Bullish

    Law firm probes Evolus over FDA warning on misleading Jeuveau promotion, stock falls 7%.

    Pomerantz LLP is investigating Evolus, Inc. following an FDA warning regarding misleading Instagram promotions for its wrinkle treatment...

    Pluang•10/27/26•Neutral

    Evolus, Inc. Common Stock Estimates – NASDAQ:EOLS

    This page provides financial actuals and estimates for Evolus, Inc. (EOLS) common stock listed on the Nasdaq Stock Market. Users can explore reported financial data and analyst estimates across various financial...

    TradingView•10/24/26•Neutral

    Evolus, Inc. (EOLS) stock price, news, quote and history

    This Yahoo Finance article provides a detailed overview of Evolus, Inc. (EOLS) stock, including its current price, performance metrics...

    Yahoo Finance Singapore•10/22/26•Neutral

    EOLS Valuation and Fair Value

    P/E
    -22.5x
    Forward P/E
    16.0x
    P/FCF
    -22.1x
    P/B
    -15.7x
    See GNG's fair value

    EOLS Profitability: Margins, ROIC and FCF

    Gross margin
    66.7%
    Operating margin
    -5.2%
    Net margin
    -10.8%
    ROIC
    -14.9%
    ROE
    -18730.0%
    FCF yield
    -4.5%

    EOLS Competitors

    CompanyTicker
    Delcath Systems IncDCTH
    Avita Medical LtdRCEL
    DiaMedica Therapeutics IncDMAC
    Gyre Therapeutics Inc.GYRE
    CytomX Therapeutics IncCTMX
    Evolent Health IncEVH
    Ovid Therapeutics IncOVID
    XOMA CorpXOMA

    Sector: Healthcare

    EOLS Analyst Ratings

    Consensus
    Buy
    Analysts
    6
    Strong Buy
    1
    Buy
    4
    Hold
    1
    Sell
    0
    Strong Sell
    0

    EOLS Bull Case vs Bear Case

    Bull case

    • EOLS grew quarterly revenue 21.2% year over year.
    • 83.3% of EOLS's analyst ratings are Buy or Strong Buy.

    Bear case

    • EOLS has a -10.8% net profit margin.
    • EOLS beat EPS estimates in 25.0% of its last 8 reported quarters.

    EOLS Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    -36.9%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.07
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    2 up, 1 down

    Frequently Asked Questions About EOLS

    Does EOLS pay dividends?

    Evolus Inc (EOLS) does not currently pay a regular dividend.

    What is EOLS's market cap?

    Evolus Inc (EOLS) has a market capitalization of $485.47M with a current stock price of $7.35.

    Related stocks

    Sector: Healthcare

    All stocks starting with E

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In